Form 4: Dentsply Sirona Director Clyde Hosein Receives Significant RSU Grant

Dentsply Sirona Inc. Director Clyde Hosein was granted 13,880 Restricted Stock Units (RSUs) on May 22, 2025, as part of his compensation.

Summary

• Clyde Hosein, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired 13,880 shares of common stock.
• The acquisition occurred on May 22, 2025, and was a grant of Restricted Stock Units (RSUs).
• The RSUs were granted at a price of $0, indicating they are part of compensation.
• These RSUs will vest in full, meaning restrictions will lapse, one year from the grant date.
• Following this transaction, Clyde Hosein directly beneficially owns 40,389.1225 shares of DENTSPLY SIRONA Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A director receiving an RSU grant is a standard compensation practice that aligns interests with shareholders and indicates continued commitment. It is not a direct investment by the director but rather a form of compensation, which is generally viewed favorably for governance and alignment.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The acquisition of 13,880 shares increases the director's direct beneficial ownership, demonstrating continued commitment to the company.

Risks

• The value of the RSU grant is subject to the future performance of DENTSPLY SIRONA Inc.'s stock price; if the stock price declines, the value of the vested shares will also decrease.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in full one year from the grant date, indicating a future increase in the director's unrestricted shareholdings.

Industry Context

This transaction is a routine part of executive and director compensation packages in publicly traded companies across various industries, including the dental products and technology sector where Dentsply Sirona operates. Equity grants like RSUs are common tools used to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across many industries, including healthcare and medical device companies, aligning with corporate governance best practices.
• While specific grant sizes vary by company size, industry, and individual role, the mechanism of granting equity at a $0 cost, with a vesting period, is consistent with typical RSU programs seen at comparable companies like Align Technology (ALGN) or Zimmer Biomet (ZBH) for their non-employee directors.

Management Changes

Corporate Governance

Related Party Transactions

• The RSU grant to Director Clyde Hosein constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value, as the value of the compensation is directly tied to the company's stock performance. It also represents a potential future dilution if the shares are newly issued upon vesting, though often such grants are covered by existing share pools.
• Employees: While not directly impacted by this specific director grant, the company's overall compensation philosophy, including equity grants, can influence employee morale and retention.

Next Steps

• The 13,880 Restricted Stock Units are expected to vest in full on May 22, 2026, one year from the grant date.

Key Dates

Keywords

Dentsply Sirona, XRAY, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Compensation, Beneficial Ownership